pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

pharmaphorum

FEBRUARY 12, 2021

The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.

Drugs 109

Drugs Sales Pharma Companies Marketing 109

pharmaphorum

JUNE 14, 2021

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021.

Drugs 99

Drugs Pharma Companies Licensing Licensing 99

pharmaphorum

FEBRUARY 3, 2022

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. The two drugs were developed by medical cannabis pioneer GW Pharma, which was acquired by Jazz last year.

Licensing 116

Licensing Licensing Marketing Medicine 116

pharmaphorum

APRIL 19, 2022

RudaCure is a four-year-old biotech company based in the South Korea, focusing on ocular disease and chronic pain with a pair of potentially first-in-class drugs. The company recently raised $16.5 So] we are trying to go for the international market.”. “In RudaCure’s key differentiators. Early successes at home.

Marketing 52

Marketing Clinical Trials Clinical Trials Licensing 52

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 96

Drugs Antibody Pharma Companies Development 96

pharmaphorum

MAY 20, 2022

In one of the first moves by a member of ATOM, Novartis has agreed to license rights to its tyrosine kinase inhibitor drug nilotinib – sold as Tasigna as a leukaemia treatment – to the UN-backed Medicines Patent Pool (MPP). The post Coalition aims to improve cancer drug access in poorer nations appeared first on.

Drugs 108

Drugs Medicine Licensing Licensing 108

Fossil Remedies

SEPTEMBER 23, 2022

PCD Pharma Franchise is a popular business model. It is a business arrangement in which a pharma company offers the rights of marketing and distribution to its franchise partner. The pharma company thus expands its business and reaches new regions. Check the market reputation and image of the company.

Pharma Companies 52

Pharma Companies Production Licensing Licensing 52

World of DTC Marketing

APRIL 12, 2021

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. We can’t continue to develop drugs the same way as we have done before.

Generic Drugs 187

Generic Drugs Manufacturing Production Drugs 187

pharmaphorum

MAY 17, 2021

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. Arecor has four active licensing agreement in place with partners including Hikma and Inhibrx.

Insulin 52

Insulin Production Marketing Pharma Companies 52

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharmaceutical Technology

AUGUST 1, 2022

The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines. As a result, multiple vaccines, including Pfizer /BioNTech’s mRNA vaccine, Comirnaty, were licensed for use within a year of development beginning. The most significant challenge, however, is solving the lack of market incentive.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

Drug Discovery World

FEBRUARY 5, 2024

However, two-thirds (68%) of patients are comfortable receiving medicines before they’re licensed through their country’s healthcare system. The new data was released by pharma company Clinigen to mark the start of Rare Disease Month.

Medicine 52

Medicine Pharma Companies Licensing Licensing 52

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

AUGUST 25, 2021

Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. We went back to what we do best … we engaged our network of companies.

Marketing 52

Marketing Licensing Licensing Manufacturing 52

pharmaphorum

FEBRUARY 11, 2022

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. billion takeover of Clementia Pharma in 2019. billion of its revenues last year. billion of its revenues last year.

Sales 93

Sales Pharma Companies Branding Cosmetics 93

pharmaphorum

JUNE 2, 2021

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic dermatitis or eczema. . Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

DECEMBER 6, 2022

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but in fact it comes from diminutive biotech Summit Therapeutics.

Licensing 52

Licensing Licensing Antibody Clinical Trials 52

pharmaphorum

JANUARY 20, 2022

The mission to treat people who suffer from allergic rhinitis has been given a boost as two pharma companies join forces. This partnership will provide patients access to a highly effective and proven treatment for allergic rhinitis in these key South-East Asian markets.”.

Allergies 70

Allergies Marketing Manufacturing Production 70

pharmaphorum

JANUARY 8, 2021

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate.

Licensing 52

Licensing Licensing Pharma Companies Branding 52

Camargo

SEPTEMBER 23, 2020

Panel Summary from the World Orphan Drug Congress 2020. Last month, executives from leading international biopharma companies came together at the World Orphan Drug Congress 2020 to discuss how they are evaluating new opportunities in the rare disease space. Thomas Kassberg, Chief Business Officer, Ultragenyx.

Business Development 136

Business Development Drugs Development Production 136

pharmaphorum

FEBRUARY 15, 2022

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion in exercise fees and milestone payments, as well as tiered royalties should any of the ADCs reach the market.

Antibody 52

Antibody Licensing Licensing Drugs 52

Fossil Remedies

AUGUST 21, 2019

A pharma franchise business model is when a company permits to sell the products by its name. It is an agreement between a franchiser which is typically a pharma manufacturing (or marketing) company where a franchisee is an individual entrepreneur or a small company that buys the license.

Pharma Companies 40

Pharma Companies Production Licensing Licensing 40

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. However, to invest in drug development for this condition, a number of methodological issues will need to be addressed.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

JANUARY 6, 2022

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. In that respect it follows a similar model to Merck’s takeover of AmpTec, another CDMO that uses a PCR platform to make mRNA drugs, for an undisclosed sum last year.

Vaccination 98

Vaccination Vaccine Manufacturing Life Science 98

pharmaphorum

APRIL 22, 2021

In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs in its pipeline, as well as potential acquisitions. The company has an “asset focused” R&D philosophy , where development is centred on the needs of each individual biotech.

Licensing 54

Licensing Licensing Pharma Companies Drugs 54

pharmaphorum

SEPTEMBER 20, 2021

For the pharma industry, the pandemic’s changes were both abrupt and industry-altering, requiring companies to rapidly adapt their approaches to drug development and commercialisation. It also led to changes in how we manufacturer, market and ship medications. Personalisation is Key.

Sales 96

Sales Marketing Pharma Companies Licensing 96

Delveinsight

AUGUST 2, 2020

The dynamics of the cancer cachexia market is expected to gain momentum as several companies are testing the waters, advancing cancer cachexia pipeline. Phase II randomised, double-blind, placebo-controlled study demonstrated that the drug as well-tolerated and a higher dose even helped in gaining weight.

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

JUNE 4, 2021

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline. . The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 62

Antibody Licensing Licensing Protein 62

pharmaphorum

MARCH 8, 2022

Bristol-Myers Squibb’s blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 It is expecting sales of the drug to shrink to between $9.5 billion in sales last year.

Sales 52

Sales Marketing Pharma Companies Licensing 52

Fossil Remedies

APRIL 26, 2022

PCD Pharma Business Plan. In a pharmaceutical business, you need a link between the pharma marketing company and the end-user, i.e., doctors, pharmacists, or others who can prescribe the medicine. This connecting link is the PCD Pharma Business. The first thing is a market research. Gather all documents.

Doctors 59

Doctors Doctor Marketing Production 59

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. Interest in the target has also prompted a flurry of licensing deals.

Antibody 91

Antibody Protein Gene Therapy Pharma Companies 91

pharmaphorum

NOVEMBER 30, 2022

The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e.

Life Science 97

Life Science Pharma Companies Sales Marketing 97

pharmaphorum

SEPTEMBER 19, 2022

French pharma company Genfit has reached a deal to buy Versantis of Switzerland, adding three development-stage drug candidates to its portfolio of experimental liver disease therapies and continuing a strategy change first unveiled in 2020. Genfit thinks HE could be a $2 billion market opportunity.

Drugs 52

Drugs Development Pharma Companies Clinical Trials 52

pharmaphorum

DECEMBER 28, 2022

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. But what steps can the smaller companies at the cutting edge take to make them acquisition-ready and maximise their value during this process?

Compliance 115

Compliance Regulation Manufacturing Licensing 115

pharmaphorum

DECEMBER 9, 2022

The deal – which included a $50 million upfront payment and up to $450 million in follow-up payments – had advanced the RMC-4630 drug candidate from preclinical testing to a phase 2 trial in combination with Amgen’s first-to-market KRAS inhibitor Lumakras (sotorasib) as a treatment for KRASG12C mutated non-small cell lung cancer (NSCLC).

Pharma Companies 57

Pharma Companies Licensing Licensing Trials 57